HLA-A and neoplasm: The HLA-A*02:01 and 24:02 are two of the most frequent alleles at global scale (about 40%), these findings imply that the vast majority of cancer patients at global level (> 50%) cannot benefit from tumor-specific shared mutated neoantigens.